for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novacyt SA

ALNOV.PA

Latest Trade

1.89EUR

Change

0.13(+7.50%)

Volume

5,741,225

Today's Range

1.76

 - 

1.92

52 Week Range

0.06

 - 

2.67

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
1.76
Open
1.77
Volume
5,741,225
3M AVG Volume
293.04
Today's High
1.92
Today's Low
1.76
52 Week High
2.67
52 Week Low
0.06
Shares Out (MIL)
37.66
Market Cap (MIL)
128.04
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Novacyt Signs Global Distribution Agreement With Bruker For Covid-19 Diagnostic Test

Novacyt Signs Agreement With Yourgene Health To Support Demand For COVID-19 Tests

Bruker Announces Launch Of CE-Ivd Marked Genesig Assay Kit For Detection Of Sars-Cov-2 Virus

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novacyt SA

Novacyt SA is a France-based company that develops and markets solutions dedicated to the field of liquid-based cytology and molecular biology. The Company develops a secure automated cytology named NovaPrep Processor System. Novacyt SA offers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles specifically dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of over 10 distributors.

Contact Info

13 avenue Morane Saulnier

78140

France

+33.1.39465104

https://novacyt.com/

Executive Leadership

James Christopher Wakefield

Independent Non-Executive Chairman

Graham D. Mullis

Chief Executive Officer, Executive Director, Member of the Executive Team

Anthony William Dyer

Chief Financial Officer, Executive Director, Company Secretary, Member of the Executive Team

Wendy Karban

Member of the Executive Team, Group Human Resource Manager

Mandy Cowling

Member of the Executive Team, Corporate & Investor Relations Manager

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
9.21
Price To Book (MRQ)
3.86
Price To Cash Flow (TTM)
815.53
Total Debt To Equity (MRQ)
45.91
LT Debt To Equity (MRQ)
20.72
Return on Investment (TTM)
-5.97
Return on Equity (TTM)
-4.29

Latest News

Latest News

Novacyt and Yourgene Health to produce coronavirus test products in UK

Healthcare companies Novacyt and Yourgene Health Plc said on Wednesday that they would be teaming up to produce coronavirus testing products in the United Kingdom.

BRIEF-Novacyt Signs Agreement With Yourgene Health To Support Demand For COVID-19 Tests

* CONTRACT MANUFACTURING SERVICES AGREEMENT SIGNED WITH YOURGENE HEALTH PLC

BRIEF-Novacyt Signs Global Distribution Agreement With Bruker For Covid-19 Diagnostic Test

* GLOBAL DISTRIBUTION AGREEMENT WITH BRUKER FOR COVID-19 DIAGNOSTIC TEST

Healthcare group Novacyt wins U.S. approval for coronavirus test

Novacyt, a healthcare company specializing in clinical diagnostics, announced on Monday approval from the U.S. Food & Drug Administration (FDA) regulator for its product aimed at testing for coronavirus.

BRIEF-Novacyt To Increase Manufacturing Capacity In Face Of Increasing Demand For COVID-19 Tests

* CORONAVIRUS TEST UPDATE: SIGNIFICANT INCREASE IN DEMAND, FURTHER EXPANSION OF MANUFACTURING CAPACITY

Healthcare group Novacyt wins British orders for coronavirus testing product

Novacyt, a healthcare company specializing in clinical diagnostics, said on Monday the British government had started on orders for its product that is aimed at carrying out tests on the coronavirus that has killed thousands across the world.

BRIEF-Novacyt Expects Increase In Number Of NHS Hospitals Purchasing Primerdesign's COVID-19 Test

* HAS INVESTED IN A SIGNIFICANT INCREASE IN MANUFACTURING CAPACITY TO SUPPORT GROWING DEMAND FOR ITS COVID-19 TEST.

Biotech group Novacyt announces deals for coronavirus test product

Biotechnology company Novacyt <ALNOV.PA> <NCYT.L> on Friday announced deals for its "Primerdesign" product which is aimed at testing for the coronavirus currently afflicting China and other parts of the world.

Biotech group Novacyt announces deals for coronavirus test product

Biotechnology company Novacyt on Friday announced deals for its "Primerdesign" product which is aimed at testing for the coronavirus currently afflicting China and other parts of the world.

BRIEF-Novacyt Issues 6.4 Million New Ordinary Shares

* ANNOUNCES THAT IT HAS ISSUED TOTAL OF 6,370,728 NEW ORDINARY SHARES OF EUR 1/15 EACH IN CAPITAL OF COMPANY ("ORDINARY SHARES") PURSUANT TO EXERCISE OF WARRANTS

BRIEF-Novacyt Announces Exercise Of Warrants And Issue Of Equity

* ADMISSION OF NEW ORDINARY SHARES TO TRADING ON EURONEXT IS EXPECTED TO OCCUR ON OR BEFORE 24 FEBRUARY 2020.

BRIEF-Novacyt - Exercise of Warrants and Issue of Equity

* ANNOUNCES IT RECEIVED NOTICE FROM ACCENT GRAVE BV OF EXERCISE OF WARRANTS TO SUBSCRIBE FOR 1,000,000 NEW ORDINARY SHARES OF EUR 1/15 EACH IN CAPITAL OF COMPANY

BRIEF-Novacyt Receives Notice Of Exercise Of Warrants To Subscribe For New Shares

* HAS RECEIVED NOTICE FROM YA II CD, LTD OF AN EXERCISE OF WARRANTS TO SUBSCRIBE FOR 228,541 NEW ORDINARY SHARES OF EUR 1/15 EACH IN CAPITAL OF COMPANY ("ORDINARY SHARES")

BRIEF-Novacyt Launches CE-IVD Marked Novel Coronavirus Test

* LAUNCHED ITS CE-MARK MOLECULAR TEST FOR CLINICAL DETECTION OF NOVEL CORONAVIRUS (COVID-19)

Biotech firm Novacyt to launch coronavirus test next week

Biotechnology company Novacyt said on Friday it would launch a certified test for the coronavirus next week, sending its London-listed shares to a record high.

Coronavirus-product testing group Novacyt shares surge again

Shares in biotech company Novacyt , which is launching a coronavirus test, surged on Monday to extend previous big gains made this year on investor hopes it could win regulatory approval for its coronavirus test product.

Biotech company Novacyt seeks emergency approval for coronavirus test

Biotechnology company Novacyt has applied for emergency approval from the U.S. Food & Drug Administration (FDA) as it races to roll out a product that tests for the coronavirus, the company said on Friday.

French biotech Novacyt seeks emergency FDA approval for coronavirus test product

Biotechnology company Novacyt <ALNOV.PA> <NCYT.L> said on Friday it has applied for emergency approval from the U.S. Food & Drug Administration (FDA) for a test product for the coronavirus that has killed almost 640 people.

French biotech Novacyt seeks emergency FDA approval for coronavirus test product

Biotechnology company Novacyt said on Friday it has applied for emergency approval from the U.S. Food & Drug Administration (FDA) for a test product for the coronavirus that has killed almost 640 people.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up